UroGen Pharma Ltd. Logo

UroGen Pharma Ltd.

Develops non-surgical therapies for urological cancers using proprietary hydrogel technology.

URGN | US

Overview

Corporate Details

ISIN(s):
IL0011407140
LEI:
Country:
United States of America
Address:
9 HA'TA'ASIYA ST, 4365007 RA'ANANA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

UroGen Pharma Ltd. is a biotechnology company dedicated to developing and commercializing innovative solutions for urothelial and other specialty cancers. The company focuses on creating transformative, non-surgical therapies for urological diseases. Its lead commercial product, ZUSDURI™, is an FDA-approved medicine for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). UroGen utilizes its proprietary RTGel™ reverse-thermal hydrogel technology to enable sustained local delivery of therapeutic agents, aiming to improve patient outcomes and revolutionize the treatment paradigm in uro-oncology.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all UroGen Pharma Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for UroGen Pharma Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for UroGen Pharma Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ODI Pharma AB Logo
Distributes pharmaceutical medicinal cannabis products across Eastern Europe, with a focus on Poland.
Sweden
ODI
Olema Pharmaceuticals, Inc. Logo
A clinical-stage biopharma developing targeted therapies for women's cancers, focusing on breast cancer.
United States of America
OLMA
OliX Pharmaceuticals, Inc. Logo
Developing RNAi therapeutics for dermatology, ophthalmology, and metabolic diseases via an asiRNA platform.
South Korea
226950
OMEROS CORP Logo
Develops first-in-class therapeutics for challenging diseases with unmet medical needs.
United States of America
OMER
ONCODESIGN Logo
Developing precision oncology solutions for resistant and metastatic cancers.
France
ALONC
Oncodesign Precision Medicine S.A Logo
Develops precision therapies & diagnostics for resistant and metastatic cancers.
France
ALOPM
Oncoinvent ASA Logo
Developing alpha-emitting radiotherapies for treating cancers in the peritoneal cavity.
Norway
OCIN
Oncolys BioPharma Inc. Logo
Developing oncolytic virus therapies and diagnostics for cancer and serious viral infections.
Japan
4588
ONCOLYTICS BIOTECH INC Logo
Developing an immuno-oncolytic virus to treat breast and gastrointestinal cancers.
United States of America
ONCY
Onconetix, Inc. Logo
Develops diagnostics and therapeutics for men's health and oncology markets.
United States of America
ONCO

Talk to a Data Expert

Have a question? We'll get back to you promptly.